Guardant Health, Inc.

NasdaqGS:GH Stock Report

Market Cap: US$11.4b

Guardant Health Valuation

Is GH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of GH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: GH ($88.1) is trading below our estimate of future cash flow value ($174.06)

Significantly Below Future Cash Flow Value: GH is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GH?

Key metric: As GH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GH. This is calculated by dividing GH's market cap by their current revenue.
What is GH's PS Ratio?
PS Ratio11.8x
SalesUS$982.02m
Market CapUS$11.36b

Price to Sales Ratio vs Peers

How does GH's PS Ratio compare to its peers?

The above table shows the PS ratio for GH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
BTSG BrightSpring Health Services
0.7x12.41%US$9.2b
DVA DaVita
0.8x4.38%US$10.4b
LH Labcorp Holdings
1.6x4.63%US$21.9b
DGX Quest Diagnostics
2x4.30%US$21.6b
GH Guardant Health
11.8x20.90%US$11.4b

Price-To-Sales vs Peers: GH is expensive based on its Price-To-Sales Ratio (11.8x) compared to the peer average (1.3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does GH's PS Ratio compare vs other companies in the US Healthcare Industry?

29 CompaniesPrice / SalesEstimated GrowthMarket Cap
CVS CVS Health
0.2x3.86%US$91.83b
COR Cencora
0.2x6.71%US$63.24b
CAH Cardinal Health
0.2x8.13%US$49.72b
HUM Humana
0.2x9.31%US$20.92b
GH 11.8xIndustry Avg. 1.2xNo. of Companies29PS012345+
29 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GH is expensive based on its Price-To-Sales Ratio (11.8x) compared to the US Healthcare industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is GH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.8x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: GH is expensive based on its Price-To-Sales Ratio (11.8x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$88.10
US$130.64
+48.28%
12.12%US$180.00US$90.00n/a22
Mar ’27US$93.90
US$132.57
+41.18%
13.53%US$180.00US$90.00n/a23
Feb ’27US$114.04
US$125.24
+9.82%
17.79%US$175.00US$60.00n/a21
Jan ’27US$102.14
US$114.05
+11.66%
17.78%US$155.00US$60.00n/a21
Dec ’26US$105.22
US$99.68
-5.26%
13.27%US$120.00US$60.00n/a22
Nov ’26US$93.02
US$93.82
+0.86%
13.97%US$115.00US$60.00n/a22
Oct ’26US$62.65
US$67.43
+7.64%
12.14%US$80.00US$47.00n/a23
Sep ’26US$67.42
US$61.33
-9.03%
7.95%US$70.00US$47.00n/a21
Aug ’26US$41.42
US$61.05
+47.38%
8.09%US$70.00US$47.00n/a22
Jul ’26US$50.71
US$59.66
+17.65%
8.85%US$70.00US$47.00n/a22
Jun ’26US$40.62
US$59.55
+46.59%
8.51%US$70.00US$47.00n/a23
May ’26US$48.87
US$58.48
+19.66%
10.07%US$70.00US$47.00n/a22
Apr ’26US$42.47
US$56.62
+33.32%
7.76%US$65.00US$47.00n/a21
Mar ’26US$42.55
US$56.10
+31.83%
9.46%US$65.00US$42.00US$93.9021
Feb ’26US$46.98
US$46.76
-0.46%
13.95%US$60.00US$34.00US$114.0421
Jan ’26US$30.55
US$43.20
+41.41%
13.11%US$60.00US$34.00US$102.1420
Dec ’25US$35.61
US$43.00
+20.75%
13.58%US$60.00US$34.00US$105.2220
Nov ’25US$23.00
US$41.60
+80.87%
12.66%US$50.00US$32.00US$93.0220
Oct ’25US$22.12
US$42.70
+93.04%
14.13%US$60.00US$34.00US$62.6520
Sep ’25US$25.58
US$42.70
+66.93%
14.13%US$60.00US$34.00US$67.4220
Aug ’25US$33.36
US$39.10
+17.21%
17.10%US$50.00US$28.00US$41.4220
Jul ’25US$28.26
US$37.45
+32.52%
18.66%US$47.00US$28.00US$50.7120
Jun ’25US$27.10
US$37.39
+37.97%
19.94%US$47.00US$28.00US$40.6218
May ’25US$18.26
US$38.89
+112.97%
21.25%US$50.00US$27.00US$48.8718
Apr ’25US$20.25
US$41.11
+103.02%
20.69%US$54.00US$27.00US$42.4718
Mar ’25US$18.97
US$41.50
+118.77%
19.38%US$54.00US$27.00US$42.5518
US$130.64
Fair Value
32.6% undervalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/26 05:14
End of Day Share Price 2026/03/26 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guardant Health, Inc. is covered by 32 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Michael RyskinBofA Global Research